- Q4 2023 CureVac NV Earnings Call TranscriptApr 24, 2024€2.27 (-4.70%)Earnings
- Q3 2023 CureVac NV Earnings Call TranscriptNov 14, 2023€5.35 (+6.79%)Earnings
- CureVac NV at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q4 2022 CureVac NV Earnings Call TranscriptApr 25, 2023€6.95 (-5.18%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptMar 28, 2023
- CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs TranscriptJan 06, 2023
- Q3 2022 CureVac NV Earnings Call TranscriptNov 16, 2022€7.89 (+2.04%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptJun 22, 2022
- CureVac NV at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- CureVac NV at Jefferies Healthcare Conference TranscriptJun 09, 2022
- CureVac NV at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q4 2021 CureVac NV Earnings Call TranscriptApr 28, 2022€15.2 (-1.05%)Earnings
- Q3 2021 CureVac NV Earnings Call TranscriptNov 19, 2021€36.83 (+4.54%)Earnings
- CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call TranscriptOct 12, 2021
- CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call TranscriptJul 01, 2021
- CureVac NV Updates On Clinical Trial - Corporate Call TranscriptJun 17, 2021
- Q4 2020 CureVac NV Earnings Call TranscriptApr 15, 2021€89 (+3.91%)Earnings
- CureVac N.V. - Special Call TranscriptFeb 05, 2021
CureVac NV Annual Shareholders Meeting Transcript
Ladies and gentlemen, welcome to the Extraordinary General Meeting of Shareholders of CureVac N.V. My name is Chris Tanner. I'm the Chairman of the Audit Committee and a member of the Supervisory Board of CureVac NV. I've been appointed by Jean Stéphenne, the Chairman of our Supervisory Board, to chair today's extraordinary general meeting on his behalf. First, allow me to introduce Dr. Alexander Zehnder, who's been nominated for appointment as Managing Director and Chief Executive Officer, at this meeting; and Dr. Myriam Mendila, who has been nominated for appointment as Managing Director and Chief Development Officer at this meeting. Dr. Zehnder and Dr. Mendila will have the opportunity of introducing themselves to you when it's time to vote on their respective appointments.
Also present in person today are Dr. Franz-Werner Haas, our outgoing CEO; Dr. Marco Rau, our General Counsel, who will act as Secretary of today's meeting; and our Dutch Notary, (inaudible).
Before proceeding, I will now give the floor to the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)